INTRODUCTION
============

*Helicobacter pylori* infection can be diagnosed by invasive methods using the gastric biopsied specimens or noninvasively by examining serum, urine, breath, or stool. Histological examination by Giemsa staining is usually recommended for the diagnosis, but it is difficult to visualize the bacterium when there is a low density of *H. pylori* on the gastric mucosa with atrophic and metaplastic changes \[[@b1-kjim-2016-353]\]. Limitations of histological examination include increased false negative test findings due to various density of *H. pylori* at different sites, high cost, long turnaround time, and interobserver variability \[[@b2-kjim-2016-353]\]. Therefore, in East Asian countries with a higher risk of chronic atrophic gastritis (CAG), intestinal metaplasia, and gastric cancer, noninvasive tests need to be added for a more reliable diagnosis of *H. pylori* infection.

The monoclonal-type *H. pylori* stool antigen test is a reliable test with high specificity and sensitivity \[[@b3-kjim-2016-353]\]. It detects the presence of current *H. pylori* infection, and is therefore useful for evaluating the status of *H. pylori* infection after eradication \[[@b4-kjim-2016-353],[@b5-kjim-2016-353]\]. It is useful even in the presence of severe gastric atrophy or intestinal metaplasia, and has the potential for quantitative evaluation of the intragastric *H. pylori* status \[[@b6-kjim-2016-353],[@b7-kjim-2016-353]\]. The sensitivity, specificity, and accuracy of the stool test is high, with reported rates of 93.1%, 94.6%, and 93.8%, respectively \[[@b6-kjim-2016-353]\]. Nonetheless, the diagnostic accuracy of the *H. pylori* stool antigen test can be diminished in special settings, such as the presence of upper gastrointestinal bleeding, and a small percentage of antigen-positive stools may present with other *Helicobacter* species \[[@b8-kjim-2016-353],[@b9-kjim-2016-353]\]. Moreover, there is a risk of a false negative result in cases in which eradication fails, if the test is performed within 2 weeks of eradication or with recent proton pump inhibitor intake therapy \[[@b7-kjim-2016-353],[@b9-kjim-2016-353]\]. Nevertheless, it is still uncertain whether the stool antigen test findings differ according to the degree of gastric corpus atrophy.

The serum pepsinogen (PG) assay enables the detection of the progression to advanced gastric corpus atrophy by virtue of the stepwise reduction in the PG I level and PG I/II ratio \[[@b10-kjim-2016-353],[@b11-kjim-2016-353]\]. In endemic area of *H. pylori*-infection, serum PG assay is widely used to predict the presence of gastric corpus atrophy \[[@b12-kjim-2016-353],[@b13-kjim-2016-353]\]. Gastric corpus atrophy, so-called serologic gastric atrophy, is diagnosed when the serum PG I level is of \< 70 ng/mL and the serum PG I/II ratio is of \< 3.0 \[[@b10-kjim-2016-353],[@b13-kjim-2016-353]\]. Most of the subjects with closed-type CAG do not have gastric corpus atrophy because their PG I-secreting cells located on the fundus are still intact \[[@b14-kjim-2016-353],[@b15-kjim-2016-353]\]. Moreover, only some of the subjects with open-type CAG have gastric corpus atrophy because both the serum PG I and PG II levels increase if there is still an active *H. pylori* infection inside the stomach. Gastric corpus atrophy does not occur unless there is a large amount of mucosal cell damage on the fundus, and therefore, the prevalence of gastric corpus atrophy is lower than the prevalence of CAG. Nonetheless, little is known about the link between the stool test findings and serum PG level in seroprevalent population. The aim of this study was to determine the characteristics of seropositive subjects according to their stool *H. pylori* antigen test findings, serum PG assays, and endoscopic diagnoses.

METHODS
=======

Subjects and study design
-------------------------

Consecutive adults who visited Konkuk University Medical Center for upper gastrointestinal endoscopy for a regular check-up were included in a prospective setting from 2014 to 2015 if the serum anti-*H. pylori* immunoglobulin G (IgG) test was positive. Subjects were excluded if the age was below 20 years or if there was a recent use of medication. Those with a history of *H. pylori* eradication or gastrectomy were also excluded. Subjects were not enrolled from the beginning when there was any possibility of organic disease, such as gastrointestinal bleeding, malignancy, acute infection, or other significant systemic disease, that required treatment. This study was approved by the Institutional Review Board of the Konkuk University Medical Center (No. KUH 1010575) and was registered as ClinicalTrials.gov (ID: KCT0001149, <https://cris.nih.go.kr>). It was performed in accordance with the principles of the Declaration of Helsinki and written informed consents were obtained.

Definition for *H. pylori* infection
------------------------------------

IgG titer was measured using the Chorus *H. pylori* IgG assay (DIESSE Diagnostica Senese, Monteriggioni, Italy), which has a high concurrence rate in Korean adults with the Genedia *H. pylori* enzyme-linked immunosorbent assay (ELISA; Green Cross Medical Science, Seoul, Korea) and the Vidas *H. pylori* IgG assays (BioMerieux, Marcy l'Etoile, France) \[[@b16-kjim-2016-353]\]. The value varied from 0 to 200 AU/mL, and was expressed as \> 200 AU/mL if the value exceeded the upper limit. The subjects were defined as having infection if more than two *H. pylori* test findings were positive in the serum anti-*H. pylori* IgG test, *H. pylori* stool antigen test, and gastric biopsy performed on the same day.

*H. pylori* stool antigen test
------------------------------

Fresh stool samples were collected on the same day the serum anti-*H. pylori* antibody test was performed, and were stored at --70oC for analysis. *H. pylori* antigen was analyzed using the SD *H. pylori* antigen ELISA kit (Standard Diagnostics Inc., Yongin, Korea) according to the manufacturer's instructions. Briefly, the assay utilizes a mouse anti-*H. pylori* monoclonal antibody that is adsorbed to microplate wells. Fecal samples were diluted with diluent, and were added with controls and a peroxidase- conjugated monoclonal antibody. After the addition, incubated for an hour at 37oC. Washing was done to remove unbound materials. After washing, substrate was added and sent for 10 minutes of incubation. The results were read using a spectrophotometer at 450 nm. Negative result was given when the optical density (OD) of stool *H. pylori* antigen was ≤ the negative mean OD +0.1. Positive result was subclassified into two findings. Strongly positive result was given when OD of stool *H. pylori* antigen was ≥ 3.0, and a weakly positive result was given when OD was between the mean negative OD +0.1 and 3.0.

Endoscopic examination
----------------------

Upper gastrointestinal endoscopy was performed at our center using a model GIF-H260 endoscope (Olympus, Tokyo, Japan). CAG was defined as transparent visible vessels, and metaplastic gastritis (MG) was defined as whitish patches or plaques. Nodular gastritis (NG) was defined as multiple, regular, and tiny (2 to 3 mm)-sized nodules on the antrum without color change. Erosive gastritis was defined as multiple hyperemic, raised lesions on the antrum, while chronic superficial gastritis (CSG) was defined as several hyperemic, linear streaks mainly on the greater curvature side of the antrum. Peptic ulcer disease (PUD) was defined as a deep mucosal defect suspicious for submucosal invasion. For esophageal lesions, erosive esophagitis (EE) was diagnosed when hyperemic streak(s) were found on the lower esophagus. Endoscopic findings were initially described, and one or two biopsies were done at the lesion(s) with color and/or structural changes. The biopsied specimens were fixed in 10% neutral buffered formalin. They were embedded in paraffin blocks thereafter, and were sectioned for Giemsa staining and Hematoxylin & Eosin staining.

Serum PG assay
--------------

After centrifuging the fasting serum samples, PG levels were determined by a latex-enhanced turbidimetric immunoassay (HBi Co., Anyang, Korea) as described in our previous study \[[@b13-kjim-2016-353]\]. Normal ranges for serum PG I level was defined as \> 70 ng/mL, PG II level as \< 15 ng/mL, and PG I/II ratio as \> 3.0 as described in previous studies.

Statistical analyses
--------------------

Sample size calculation was done using one correlation power analysis with a 5% significance level and a statistical power of 80%. Numeric result was calculated based on our pilot data using Ha which was between R0 (the value of the population correlation under the null hypothesis) and R1 (the value of the population correlation under the alternative hypothesis). A decision was made to enroll more than 123 *H. pylori*-infected subjects (power = 0.08022, α = 0.0500, β = 0.1978, R0 = 0.0000, R1 = 0.2500).

Using PASW version 17.0 (SPSS Inc., Chicago, IL, USA), significance was considered at a *p* value \< 0.05. Categorical variables including gender, endoscopic disgnoses, and stool antigen test findings are shown in frequency (%) using the chi-square test. Continuous variables including age and serum PG levels are shown as mean value ± standard deviation using the Student *t* test. OD values for the stool test findings are shown as median value with ranges (minimum and maximum values) using the Kruskal-Wallis test due to its skewed distributions. A receiver operating characteristic (ROC) curve was constructed by plotting sensitivity (true-positive rate) against 1-specificity (false-positive rate) over all possible threshold levels of serum PG I, PG II, and PG I/II ratio, which are related to the positive stool test findings. Logistic regression analysis was performed to verify the independent significance of variables correlated with the positive stool test findings using the odds ratio. Differences in 95% confidence interval (CI) between the groups were compared additionally. For the continuous values (age and serum PG assays), unstandardized coefficients are shown with standard error using linear logistic regression analysis.

RESULTS
=======

Characteristics of the subjects
-------------------------------

A total of 322 *H. pylori*-seropositive subjects were included in the study. Four subjects were excluded due to the poor quantity of the fecal specimens ([Fig. 1](#f1-kjim-2016-353){ref-type="fig"}). Of the 318 included subjects, stool test was positive in 256 (80.5%).

Distribution by *H. pylori* stool antigen test findings
-------------------------------------------------------

There were no differences in age and gender between the negative and positive stool test groups. Subjects with a negative stool test result displayed significantly lower serum PG I (*p* \< 0.001) and PG II (*p* \< 0.001) levels than those with the positive stool test ([Table 1](#t1-kjim-2016-353){ref-type="table"}). As a consequence, serum PG I/II ratio was higher in the negative stool test group than the positive stool test group (*p* \< 0.001).

With regard to the endoscopic findings, CAG was more common in those with a positive stool test (*p* = 0.009) and, CSG was more common in those with a negative stool test (*p* = 0.013). Logistic regression analysis revealed that none of the endoscopic diagnosis was independently related to a positive stool test finding ([Table 2](#t2-kjim-2016-353){ref-type="table"}).

Link between the serum PG assay and stool antigen test findings
---------------------------------------------------------------

On the multivariate analysis findings, serum PG I level was correlated with a positive stool test (*p* = 0.001), whereas serum PG I/II ratio was inversely related to a positive stool test (*p* = 0.001). Using the continuous values, a positive correlation was found between the stool antigen test and serum PG I (*r* = 0.269, *p* \< 0.001) and PG II (*r* = 0.407, *p* \< 0.001) titers. The stool test and serum PG I/II ratio were inversely correlated (*r* = --0.355, *p* \< 0.001). ROC curve analyses revealed optimal cut-off values for a positive stool test finding were a serum PG I level of 41.5 ng/mL (area under the curve \[AUC\], 0.723; 95% CI, 0.636 to 0.809, *p* \< 0.001), serum PG II level of 8.7 ng/mL (AUC, 0.750; 95% CI, 0.663 to 0.838; *p* \< 0.001), and PG I/II ratio of 3.35 (AUC, 0.698; 95% CI, 0.598 to 0.798; *p* \< 0.001).

Distribution by endoscopic findings
-----------------------------------

The most common endoscopic finding in 318 seropositive subjects was CAG. Eleven subjects showed normal endoscopic finding, whereas 79 had more than two diagnoses that included synchronous CAG and MG. Five of these 79 subjects were diagnosed as having three abnormal endoscopic findings (3 CAG/MG/PUD and 2 CAG/MG/EE).

The OD values of the *H. pylori* stool antigen test was significantly higher in the subjects with CAG than those without CAG (*p* = 0.026). On the contrary, it was significantly lower in the subjects with CSG (*p* = 0.022) and those with EE (*p* = 0.030) ([Table 3](#t3-kjim-2016-353){ref-type="table"}).

Significant variables related to endoscopic diagnosis
-----------------------------------------------------

The mean age of the subjects was oldest in MG (60.3 years) and youngest in NG (43.5 years). Younger subjects had more NG (*p* = 0.007), EE (*p* = 0.011), and CSG (*p* = 0.001), whereas the elderly had more CAG (*p* \< 0.001) and MG (*p* \< 0.001). On linear regression analysis ([Table 4](#t4-kjim-2016-353){ref-type="table"}), old age was an independent risk factor for the presence of MG (*p* \< 0.001) and the absence of EE (*p* = 0.043).

The mean serum PG I level was highest in the subjects with PUD, while it was lowest in those with EE. Subjects with EE showed the lowest mean serum PG II level and the highest mean PG I/II ratio. The presence of EE was significantly related to male gender (*p* \< 0.001), low serum PG I (*p* = 0.036), and PG II (*p* = 0.002) levels. Furthermore, it was correlated with a higher serum PG I/II ratio (*p* = 0.040). Linear regression analysis revealed that high serum PG I/II ratio (*p* = 0.040) and low serum PG II level (*p* = 0.004) were independent risk factors for the presence of EE.

DISCUSSION
==========

In this study, the serum PG levels were significantly increased in subjects with a positive stool test than in those with a negative stool test. Significantly increased levels of serum PG I in the subjects with a positive stool test indicated that these subjects had an active *H. pylori* infection. Different characteristics of the seropositive subjects according to their stool *H. pylori* antigen test, serum PG assay, and endoscopic findings imply that a high serum PG I level denotes an ongoing *H. pylori* infection with an increased gastric secreting ability. This further suggests that care should be taken in seropositive subjects with an elevated serum PG I level because of the presence of *H. pylori* in their fecal material.

Serology testing is used widely in East Asia due to its clinical efficacy against *H. pylori* infection \[[@b17-kjim-2016-353]\], and the serum anti-*H. pylori* IgG titer provides evidence of infection in chronic gastritis subjects even when the gastric biopsy specimens are negative \[[@b18-kjim-2016-353]\]. The stool test has the potential to be useful for the quantitative evaluation of *H. pylori* status in the stomach \[[@b8-kjim-2016-353]\], but there is a paucity of data on the stool *H. pylori* antigen test findings according to the serum PG assay and endoscopic findings. Presently, comparison of seropositive subjects with a positive stool test and those with a negative stool test revealed that the stage of *H. pylori* infection was significantly related to the presence of *H. pylori* in stool. Our study findings add to the previous findings that the presence of *H. pylori* in stool is linked to an active infection stage as reflected by increased gastric secreting ability. There may be an increased risk of disseminating larger amounts of bacteria via the feces in these seropositive subjects with a positive stool test remain untreated \[[@b19-kjim-2016-353]\].

The serum PG I levels were significantly higher and serum PG I/II ratios were lower in the positive stool group than in the negative stool group in this study. This is due to a greater increase in the serum PG II level than PG I in an infected stomach \[[@b20-kjim-2016-353]\]. PG I is secreted only at the fundus while PG II I is secreted throughout the stomach, and therefore, the serum PG II level is known to be more reliable than PG I as a marker for *H. pylori*-related gastropathies \[[@b14-kjim-2016-353],[@b15-kjim-2016-353]\]. Moreover, a recent study showed that *H. pylori*-related gastric cancers exhibit a higher serum PG II level in conjunction with a shorter allele of the PG II 100 bp ins/del polymorphism \[[@b21-kjim-2016-353]\].

Since serum PG levels increase in the presence of active *H. pylori* infections and decrease in the presence of chronic infections, our study findings indicate that most of the subjects in the stool test negative group had inactive or past infection, and could not actively disseminate the bacterium \[[@b19-kjim-2016-353]\]. This is consistent with previous studies that positivity of the stool antigen test was less accurate in the seropositive subjects with a low serology titer due to the progress of severe gastric atrophy \[[@b22-kjim-2016-353]\]. The present findings are also supported by the findings of a positive correlation between the bacterial density of the gastric mucosa and serum PG I and PG II levels \[[@b23-kjim-2016-353]\]. According to the optimal cut-off values found in this study, infected subjects with *H. pylori* in their stool might be reduced in the seropositive subjects with a serum PG I level \< 41.5 ng/mL, a PG II level \< 8.7 ng/mL, and a PG I/II ratio \> 3.3. This is due to the less bacterium in the fecal material at chronic infection stage with decreased gastric secreting ability. Their findings are consistent with our study findings that stool antigen test-positive subjects showed a higher prevalence of CAG on endoscopy than the negative subjects, but not the prevalence of gastric corpus atrophy as reflected by the serum PG assay.

Endoscopic findings are useful indicators for *H. pylori* eradication in seroprevalent populations \[[@b24-kjim-2016-353]\]. Although endoscopic diagnosis was not an independent risk factor for a positive stool test, CAG and NG were more common in the subjects with positive stool test, whereas CSG and EE were more common in those with negative stool test. These findings are consistent with gastric secretability as reflected by the lowest serum PG I and PG II levels and the highest mean PG I/II ratio in the subjects with EE.

The fecal materials were included within 24 hours of sampling to prevent the die-off of *H. pylori* after prolonged air exposure that might interrupt the survival of *H. pylori* in microaerobic conditions. Nonetheless, there are limitations in this study. First, gastric biopsies were not taken from all subjects in this study. Since we included the subjects who visited for upper gastrointestinal endoscopy for a regular check-up, gastric biopsy was not performed unless there is a suspicious lesion with color and/or structural change. Due to the lack of evaluation based on the updated Sydney system, we could not evaluate the degree of activity, inflammation, gastric atrophy, and intestinal metaplasia according to the stool antigen test findings. Second, frozen stool samples were used for evaluation instead of fresh fecal materials. Third, the results of stool test were expressed as OD values although it has been demonstrated that data expressed as OD are inappropriate for estimating the bacterial load \[[@b25-kjim-2016-353]\]. Despite these limitations, our findings indicate that once the stool test is positive, the subjects exhibit a high serum PG level regardless of the stool test OD values. A relationship between *H. pylori* stool test findings and gastric secreting ability was found depending on the degree of gastric corpus atrophy as reflected by low serum PG I level. Our findings are consistent with previous study demonstrating that *H. pylori* stool test is an useful diagnostic method even with frozen stool samples \[[@b26-kjim-2016-353]\].

In conclusion, there is a link between positive stool *H. pylori* antigen test findings and a serum PG assay in seropositive subjects. Positive stool *H. pylori* antigen test findings are common in seropositive subjects with increased serum PG I levels indicating an ongoing *H. pylori* infection. Our study findings further suggest that, to reduce the infected subjects with *H. pylori* in their fecal material, seropositive subjects with increased gastric secreting ability need to be treated.

KEY MESSAGE
===========

1\. Most (\> 80%) of the *Helicobacter pylori*-seropositive subjects showed positive stool test findings.

2\. The presence of *H. pylori* antigen in stool was independently related to a higher serum pepsinogen (PG) I level and a lower serum PG I/II ratio, which denote an active current *H. pylori* infection with increased gastric secreting ability.

3\. Seropositive subjects with increased gastric secreting ability tend to have *H. pylori* in their fecal material as reflected by a positive stool *H. pylori* antigen test finding.
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![Study flow of the included subjects. Three hundred and twenty-two subjects with serum anti-*Helicobacter pylori* immunoglobulin G (IgG) level ≥ 12.0 AU/mL were included in the study. *H. pylori* antigen was not found in stool in 62 seropositive subjects.](kjim-2016-353f1){#f1-kjim-2016-353}

###### 

Characteristics of the 318 *Helicobacter pylori*-seropositive subjects

  Variable                              All subjects (n = 318)   *H. pylori* stool antigen test                       
  ------------------------------------- ------------------------ -------------------------------- ------------------- ----------
  Age, yr                               51.5 ± 11.3              52.2 ± 11.1                      51.3 ± 11.4         0.589
  Male sex                              182 (57.2)               41 (66.1)                        141 (55.1)          0.115
  PG I, ng/mL                           63.0 ± 28.3              49.6 ± 27.2                      66.3 ± 27.6         \< 0.001
  PG II, ng/mL                          18.9 ± 10.9              12.4 ± 7.8                       20.5 ± 11.0         \< 0.001
  PG I/II                               4.00 ± 1.95              4.95 ± 2.32                      3.76 ± 1.78         \< 0.001
  Stool *H. pylori* antigen test (OD)   1.82 (0.05--4.00)        0.71 (0.05--0.15)                2.38 (0.16--4.00)   \< 0.001
  NG, present                           14 (4.4)                 1 (1.6)                          13 (5.1)            0.233
  PUD, present                          17 (5.3)                 3 (4.8)                          14 (5.5)            0.843
  CAG, present                          223 (70.1)               35 (56.5)                        188 (73.4)          0.009
  MG, present                           29 (9.1)                 7 (11.3)                         22 (8.6)            0.508
  EG, present                           42 (19.2)                11 (22.6)                        31 (18.4)           0.240
  EE, present                           35 (11.0)                11 (17.7)                        24 (9.4)            0.059
  CSG, present                          30 (9.4)                 11 (17.7)                        19 (7.4)            0.013

Values are presented as mean ± SD, number (%), or median (range).

PG, pepsinogen; OD, optical density; NG, nodular gastritis; PUD, peptic ulcers disease; CAG, chronic atrophic gastritis; MG, metaplastic gastritis; EG, erosive gastritis; EE, erosive esophagitis; CSG, chronic superficial gastritis.

###### 

Variables related to the positive stool test findings

  Variable   Univariate analysis    Multivariate analysis                                                         
  ---------- ---------------------- ------------------------------------------------------ ---------------------- -------
  Age        0.959 (0.923--0.998)   0.037                                                                         
  Sex        0.724 (0.302--1.734)   0.469                                                                         
  PG I       1.049 (1.017--1.082)   0.002^[a](#tfn1-kjim-2016-353){ref-type="table-fn"}^   1.027 (1.011--1.043)   0.001
  PG II      0.976 (0.885--1.076)   0.624                                                                         
  PG I/II    0.560 (0.379--0.830)   0.004^[a](#tfn1-kjim-2016-353){ref-type="table-fn"}^   0.750 (0.635--0.886)   0.001
  NG         0.242 (0.020--2.891)   0.262                                                                         
  PUD        0.366 (0.039--3.445)   0.380                                                                         
  CAG        0.153 (0.032--0.719)   0.017                                                                         
  MG         1.951 (0.544--6.999)   0.305                                                                         
  EG         0.495 (0.093--2.623)   0.408                                                                         
  EE         1.119 (0.382--3.277)   0.837                                                                         
  CSG        0.453 (0.078--2.642)   0.379                                                                         

OR, odds ratio; CI, confidence interval; PG, pepsinogen; NG, nodular gastritis; PUD, peptic ulcers disease; CAG, chronic atrophic gastritis; MG, metaplastic gastritis; EG, erosive gastritis; EE, erosive esophagitis; CSG, chronic superficial gastritis.

After multiple testing corrections, *p* values of \< 0.0042 were considered significant.

###### 

Findings according to the endoscopic diagnosis

  Variable        Absent              Present             *p* value
  --------------- ------------------- ------------------- -----------
  NG              304                 14                  
   Age, yr        51.9 ± 11.1         43.5 ± 13.4         0.007
   Male sex       177 (58.2)          5 (35.7)            0.096
   Stool OD       1.80 (0.05--4.00)   2.24 (0.13--4.00)   0.312
   PG I, ng/mL    63.4 ± 28.6         56.2 ± 19.1         0.436
   PG II, ng/mL   18.9 ± 11.0         18.6 ± 8.9          0.935
   PG I/II        4.0 ± 2.0           3.5 ± 1.4           0.432
  PUD             301                 17                  
   Age, yr        51.4 ± 11.4         52.2 ± 11.2         0.778
   Male sex       170 (56.5)          12 (70.6)           0.253
   Stool OD       1.81 (0.05--4.00)   1.98 (0.05--3.55)   0.943
   PG I, ng/mL    62.7 ± 28.4         68.4 ± 25.6         0.499
   PG II, ng/mL   18.9 ± 11.1         17.8 ± 8.0          0.718
   PG I/II        4.0 ± 2.0           4.2 ± 1.2           0.722
  CAG             95                  223                 
   Age, yr        47.9 ± 11.5         52.3 ± 11.0         \< 0.001
   Male sex       55 (57.9)           127 (57.0)          0.876
   Stool OD       1.27 (0.05--4.00)   2.01 (0.05--4.00)   0.026
   PG I, ng/mL    57.8 ± 26.6         65.6 ± 28.7         0.078
   PG II, ng/mL   17.3 ± 9.9          19.5 ± 11.2         0.159
   PG I/II        4.0 ± 2.1           4.0 ± 1.9           0.919
  MG              289                 29                  
   Age, yr        50.6 ± 11.1         60.3 ± 9.5          \< 0.001
   Male sex       164 (56.7)          18 (69.2)           0.581
   Stool OD       1.85 (0.05--4.00)   1.38 (0.06--3.83)   0.477
   PG I, ng/mL    63.1 ± 29.0         62.3 ± 20.8         0.894
   PG II, ng/mL   18.9 ± 11.2         18.2 ± 7.7          0.781
   PG I/II        4.0 ± 2.0           4.0 ± 1.8           0.999
  EG              276                 42                  
   Age, yr        51.6 ± 11.6         50.8 ± 9.8          0.672
   Male sex       156 (56.5)          26 (61.9)           0.511
   Stool OD       1.9 (0.05--4.00)    1.5 (0.05--3.91)    0.241
   PG I, ng/mL    63.6 ± 28.3         58.9 ± 28.8         0.421
   PG II, ng/mL   19.2 ± 11.2         16.6 ± 7.8          0.242
   PG I/II        4.0 ± 2.0           4.1 ± 1.9           0.761
  EE              283                 35                  
   Age, yr        52.1 ± 11.4         46.9 ± 9.9          0.011
   Male sex       152 (53.7)          30 (85.7)           \< 0.001
   Stool OD       1.9 (0.05--4.00)    0.68 (0.06--3.98)   0.030
   PG I, ng/mL    64.4 ± 29.1         51.6 ± 16.5         0.036
   PG II, ng/mL   19.7 ± 11.1         12.3 ± 6.1          0.002
   PG I/II        3.9 ± 2.0           4.8 ± 1.6           0.040
  CSG             288                 30                  
   Age, yr        52.2 ± 11.3         44.9 ± 9.9          0.001
   Male sex       162 (56.3)          20 (66.6)           0.272
   Stool OD       1.91 (0.05--4.00)   0.42 (0.05--3.83)   0.022
   PG I, ng/mL    64.1 ± 29.0         52.0 ± 17.0         0.068
   PG II, ng/mL   19.2 ± 10.6         15.6 ± 13.4         0.154
   PG I/II        4.0 ± 2.0           4.1 ± 1.7           0.850

Values are presented as mean ± SD, number (%), or median (range).

NG, nodular gastritis; OD, optical density; PG, pepsinogen; PUD, peptic ulcers disease; CAG, chronic atrophic gastritis; MG, metaplastic gastritis; EG, erosive gastritis; EE, erosive esophagitis; CSG, chronic superficial gastritis.

###### 

Linear regression analysis based on the endoscopic findings

  Variable   Unstandardized coefficient                                                                                      
  ---------- ---------------------------- ---------- ------------------- ------- ----------------- ------- ----------------- -------
  NG         --7.391 (3.749)              0.050      --10.757 (10.979)   0.328   --2.314 (4.194)   0.582   --0.339 (0.765)   0.658
  PUD        --1.074 (2.699)              0.691      4.626 (8.425)       0.583   --1.748 (3.218)   0.588   0.280 (0.587)     0.633
  CAG        1.345 (2.873)                0.640      --2.095 (8.184)     0.798   --1.537 (3.126)   0.623   0.201 (0.570)     0.725
  MG         8.402 (2.143)                \< 0.001   --3.529 (6.613)     0.594   --1.308 (2.526)   0.605   --0.047 (0.461)   0.919
  EG         0.609 (3.210)                0.850      --7.841 (9.415)     0.406   --3.881 (3.597)   0.282   0.180 (0.656)     0.784
  EE         --4.016 (1.972)              0.043      --10.465 (6.219)    0.094   --6.894 (2.376)   0.004   0.895 (0.433)     0.040
  CSG        --5.013 (3.437)              0.146      --14.012 (10.186)   0.170   --4.545 (3.891)   0.244   0.108 (0.710)     0.880

PG, pepsinogen; SE, standard error; NG, nodular gastritis; PUD, peptic ulcers disease; CAG, chronic atrophic gastritis; MG, metaplastic gastritis; EG, erosive gastritis; EE, erosive esophagitis; CSG, chronic superficial gastritis.
